Format

Send to

Choose Destination
Expert Rev Hematol. 2018 Mar;11(3):169-184. doi: 10.1080/17474086.2018.1436965. Epub 2018 Feb 19.

GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Author information

1
a Division of Hematology/Oncology , Northwestern University , Chicago , IL , USA.
2
b Department of Medicine , Campus Biomedico , Rome , Italy.
3
c National Center for Drug Research and Evaluation, Istituto Superiore di Sanità , Roma , Italy.
4
d Department of Biomedical and Neuromotorial Sciences , Alma Mater University , Bologna , Italy.
5
e Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (ISMMS) , New York , NY , USA.

Abstract

GATA1, the founding member of a family of transcription factors, plays important roles in the development of hematopoietic cells of several lineages. Although loss of GATA1 has been known to impair hematopoiesis in animal models for nearly 25 years, the link between GATA1 defects and human blood diseases has only recently been realized. Areas covered: Here the current understanding of the functions of GATA1 in normal hematopoiesis and how it is altered in disease is reviewed. GATA1 is indispensable mainly for erythroid and megakaryocyte differentiation. In erythroid cells, GATA1 regulates early stages of differentiation, and its deficiency results in apoptosis. In megakaryocytes, GATA1 controls terminal maturation and its deficiency induces proliferation. GATA1 alterations are often found in diseases involving these two lineages, such as congenital erythroid and/or megakaryocyte deficiencies, including Diamond Blackfan Anemia (DBA), and acquired neoplasms, such as acute megakaryocytic leukemia (AMKL) and the myeloproliferative neoplasms (MPNs). Expert commentary: Since the first discovery of GATA1 mutations in AMKL, the number of diseases that are associated with impaired GATA1 function has increased to include DBA and MPNs. With respect to the latter, we are only just now appreciating the link between enhanced JAK/STAT signaling, GATA1 deficiency and disease pathogenesis.

KEYWORDS:

GATA1; congenital anemias; erythropoiesis; myelofibrosis; myeloproliferative disorders; ribosome deficiencies

PMID:
29400094
PMCID:
PMC6108178
DOI:
10.1080/17474086.2018.1436965
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center